Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study

Multiple Myeloma (MM)

Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study

Clin Cancer Res

Suvannasankha A, Li M, Omofuma O, Hampp C, Phelan M, Breskin A, Shao P, Roccia T, Mukherjee N, Shrestha A, Lee D, Glass J, Kroog GS, Rodriguez Lorenc K

doi: 10.1158/1078-0432.CCR-25-4068

Multiple Myeloma (MM)

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

Blood Cancer J

Varga C, Robinson M, Davis JA, Hashmi H, Martin TG, Kumar A, Sborov DW, Wagner CB, Hansen DK, Castaneda Puglianini O, Shune L, Bhurtel E, Afrough A, Anderson LD Jr, Dhakal B, Herr MM, Richard S, Lieberman-Cribbin A, Sherbenou D, Forsberg PA, Purvey S, Khouri J, Lin Y, Sidana S, Patel KK, Kocoglu M, Midha S, Ferreri CJ

doi: 10.1038/s41408-026-01469-z

Lymphoma

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study

Eur J Cancer

Fabbri N, Casadei B, Chiappella A, Stella F, Donzelli L, Galli E, Riva M, Martino M, Barbui AM, Musso M, Farina M, Angelillo P, Cutini I, Santoro A, Cavallo F, Rivela P, Castellino A, Krampera M, Petruzzellis G, Grillo G, Argnani L, Bonifazi F, Corradini P, Zinzani PL

doi: 10.1016/j.ejca.2026.116879

EHA/ICML 2025

Lymphoma

Expanding the Curative Potential of CAR T-Cell Therapy

Lymphoma

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Blood

Brooks TR, Zabor EC, Bedelu Y, Yang X MD, Karimi YH, Nedved AN, Wang Y, Dave NK, Landsburg DJ, Baron K, Hu B, Trotier D, Pophali PA, Miller J PharmD, Grover NS, Reinert C, Major A, Schwarz T, Patel K, Salafian K MD, Ayers EC, Sundaram S, Brody JD, McKenna M, Tiger YKR, Sears-Smith M, Ghosh N, Peterson C DO, Khan C, Bliven SP MD, Narkhede M, Gibson A, Kline J, Munoz J, Garza Morales R, Ho C, Smith SD, Niu A MD, Hernandez-Ilizaliturri FJ, Chinyengetere F MDPhD, Dave SS, Abdel-Razeq N, Alhaj Moustafa M, Caimi P, Hill BT

doi: 10.1182/blood.2025029117

ASH 2025

Lymphoma

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

Lymphoma

Allogeneic hematopoietic stem cell transplantation following T-cell-directed immunotherapy failure in B-cell lymphoma: a real-world case series and systematic literature review

Leuk Lymphoma

Kim DH, Cha S, Koh Y, Byun JM

doi: 10.1080/10428194.2026.2638438

Lymphoma

CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study

Haematologica

Magni M, Jonnalagadda S, Bonifazi F, Bonafe M, Ljevar S, Zanirato G, De Matteis S, Stella F, Barone A, Bertolini G, Bermema A, Chiappella A, Tisi MC, Cutini I, Novo M, Grillo G, Farina M, Martino M, Krampera M, Massaia M, Arcaini L, Bramanti S, Zinzani PL, Dodero A, Corradini P, Carniti C

doi: 10.3324/haematol.2025.287528

Lymphoma

CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis

Am J Hematol

Gauthier J, Ahn KW, Patel J, Lian Q, Badawy S, Cairo MS, Delgado J, Grover N, Haverkos B, de Lima M, Malone A, Mussetti A, Nieto Y, Pawarode A, Pearson L, Solh M, Sureda A, Tun AM, Wudhikarn K, Yamshon S, Shadman M, Turtle CJ, Hamadani M, Herrera AF

doi: 10.1002/ajh.70033

Related content

Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study

Expanding the Curative Potential of CAR T-Cell Therapy

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

Allogeneic hematopoietic stem cell transplantation following T-cell-directed immunotherapy failure in B-cell lymphoma: a real-world case series and systematic literature review

CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study

CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis